Dianthus Therapeutics (DNTH) Insider Trading & Ownership $23.80 +0.76 (+3.30%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Dianthus Therapeutics (NASDAQ:DNTH) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.56%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$1.31 MNumber OfInsiders Selling(Last 3 Years)0 Get DNTH Insider Trade Alerts Want to know when executives and insiders are buying or selling Dianthus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address DNTH Insider Buying and Selling by Quarter Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Dianthus Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/29/2023Fairmount Funds Management LlcDirectorBuy24,670$13.63$336,252.10 9/26/2023Fairmount Funds Management LlcDirectorBuy30,000$13.15$394,500.00 9/21/2023Simrat RandhawaInsiderBuy2,000$13.20$26,400.00 9/19/2023Fairmount Funds Management LlcDirectorBuy30,000$13.20$396,000.00 9/12/2023Fairmount Funds Management LlcDirectorBuy14,887$10.85$161,523.95 (Data available from 1/1/2013 forward) DNTH Insider Trading Activity - Frequently Asked Questions Who is on Dianthus Therapeutics's Insider Roster? The list of insiders at Dianthus Therapeutics includes Fairmount Funds Management Llc, and Simrat Randhawa. Learn more on insiders at DNTH. What percentage of Dianthus Therapeutics stock is owned by insiders? 16.56% of Dianthus Therapeutics stock is owned by insiders. Learn more on DNTH's insider holdings. Which Dianthus Therapeutics insiders have been buying company stock? The following insiders have purchased DNTH shares in the last 24 months: Fairmount Funds Management Llc ($1,288,276.05), and Simrat Randhawa ($26,400.00). How much insider buying is happening at Dianthus Therapeutics? Insiders have purchased a total of 101,557 DNTH shares in the last 24 months for a total of $1,314,676.05 bought. Dianthus Therapeutics Key ExecutivesMr. Marino Garcia M.B.A. (Age 58)President, CEO, Secretary & Director Compensation: $496.02kMr. Ryan Savitz (Age 35)CFO and Chief Business Officer & Treasurer Compensation: $329.65kMr. Simrat Randhawa M.B.A. (Age 54)M.D., Chief Medical Officer Compensation: $338.16kMr. Edward G. Carr (Age 55)Chief Accounting Officer Mr. Judson TaylorHead of Technical OperationsDr. Jeffrey Stavenhagen Ph.D.Chief Scientific OfficerMs. Jennifer Davis RuffVP and Head of Investor Relations & Corporate Affairs.Mr. Adam M. Veness Esq. (Age 38)Senior VP, General Counsel & Secretary Ms. Kristina MaximenkoChief People OfficerMs. Rashieda GluckHead of Clinical Development Operations More Insider Trading Tools from MarketBeat Related Companies SpringWorks Therapeutics Insider Trades Zai Lab Insider Trades Vericel Insider Trades Gemini Therapeutics Insider Trades Kymera Therapeutics Insider Trades Vera Therapeutics Insider Trades Bausch Health Companies Insider Trades Arrowhead Pharmaceuticals Insider Trades Dyne Therapeutics Insider Trades Catalyst Pharmaceuticals Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:DNTH) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNTH Stock Alerts